Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent Acquires R.P. Scherer Eberbach

Published: Friday, March 02, 2012
Last Updated: Thursday, March 01, 2012
Bookmark and Share
Company continues to expand global softgel drug delivery capabilities.

Catalent Pharma Solutions has announced that it has completed the acquisition, from Gelita AG, of the remaining 49% minority interest in the R.P. Scherer GmbH & Co. KG, Eberbach, Germany business (“R.P. Scherer Eberbach”).

After 60 years of joint partnership, Catalent and Gelita agreed that the R.P. Scherer Eberbach business will be better able to serve the growing European pharmaceutical and consumer health softgel market with R.P. Scherer fully integrated into Catalent.

Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.

R.P. Scherer Corporation (including the Eberbach joint venture) was founded by the inventor of the rotary die production process for softgel capsules and was sold to Cardinal Health PTS, which is now Catalent Pharma Solutions.

Catalent and R.P. Scherer Eberbach have a long heritage of experience, know-how and recognized expertise in softgel formulation and operations.

“We are proud of the strong Catalent and R.P. Scherer Eberbach legacy and are very excited about the future of softgel innovation as an important part of the development, delivery and market supply of pharmaceutical and nutraceutical products. This acquisition comes on the heels of on-going extensive investments that Catalent is making in its softgel facilities in Buenos Aires, Argentina; Aprilia, Italy; and St. Petersburg, Florida; and other investments in advanced drug delivery technologies in Germany and the US,” said David Heyens, President of Catalent’s Softgel Business.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
Company provide of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services.
Friday, February 05, 2016
Catalent Announces Launch of Catalent Applied Drug Delivery Institute
Launch of Institute at the 2012 AAPS Annual Meeting and Exposition, Chicago, IL.
Thursday, October 25, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!